Optimizing antidotal treatment with the oral hsp90 inhibitor tas-116 against hydrochloric acid-induced pulmonary fi brosis in mice

HIGHLIGHTS

• who: Hsp and collaborators from the University of Kansas Medical Center, United States have published the Article: Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fi brosis in mice, in the Journal: (JOURNAL) of 15/03/2022
• what: The authors investigated the optimal dosing and windows of administration of TAS-116 against HCl-induced pulmonary fibrosis and chronic lung injury in mice. The authors used three different doses in search of the minimal effective dose against HCl-challenged animals showed a decrease in pressurevolume (PV) loops . The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.